Cardiovascular risk factors and prevention of cardiovascular disease in patients with chronic renal disease

Bibliography

• Lopez AD, Mathers CD, Ezzati M, Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-57
   PubMed Web of Science ®Google Scholar
• Anderson GF, Chu E. Expanding priorities – confronting chronic disease in countries with low income. N Engl J Med 2007;356:209-11
   PubMed Web of Science ®Google Scholar
• McClellan WM, Langston RD, Presley R. Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol 2004;15:1912-19
   PubMed Web of Science ®Google Scholar
• Elsayed EF, Tighiouart H, Griffith J, Cardiovascular disease and subsequent kidney disease. Arch Intern Med 2007;167:1130-6
   PubMed Web of Science ®Google Scholar
• Knauf F, Aronson PS. ESRD as a window into America's cost crisis in health care. J Am Soc Nephrol 2009;20:2093-7
   PubMedGoogle Scholar
• El Nahas M, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005;365:331-40
   PubMed Web of Science ®Google Scholar
• Clase CM, Garg AX, Kiberd BA. Prevalence of low glomerular filtration rate in nondiabetic americans: third national health and nutrition examination survey (NHANES III). J Am Soc Nephrol 2002;13:1338-49
   PubMedGoogle Scholar
• Coresh J, Selvin E, Stevens LA, Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47
   PubMed Web of Science ®Google Scholar
• Coresh J, Eknoyan G, Levey AS. Estimating the prevalence of low glomerular filtration rate requires attention to the creatinine assay calibration. J Am Soc Nephrol 2002;13:2811-12; reply by authors 2812-16
   PubMedGoogle Scholar
• Xue JL, Ma JZ, Louis TA, Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001;12:2753-8
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12
   PubMed Web of Science ®Google Scholar
• Glassock RJ, Winearls C. Diagnosing chronic kidney disease. Curr Opin Nephrol Hypertens 2010;19:123-8
   PubMedGoogle Scholar
• Jones CA, McQuiln GM, Kusek JW, Serum creatinine levels in the US population: third national health examination survey. Am J Kidney Dis 1998;32:992-9
   PubMed Web of Science ®Google Scholar
• Wen CP, Cheng TY, Tsai MK, All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462,293 adults in Taiwan. Lancet 2008;371:2173-82
   PubMed Web of Science ®Google Scholar
• Tonelli M, Wiebe N, Culleton B, Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17:2034-47
   PubMed Web of Science ®Google Scholar
• Keith DS, Nichols DA, Guillion CM, Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659-3
   PubMed Web of Science ®Google Scholar
• De LS, Chan T, Stevens P, Identifying patients with chronic kidney disease from general practice computer records. Fam Pract 2005;22:234-41
   PubMedGoogle Scholar
• Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial 2003;16:101-5
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Harnett JD, Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-92
   PubMed Web of Science ®Google Scholar
• Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Wave 3 and 4 study. Kidney Int 2002;62:1784-90
   PubMed Web of Science ®Google Scholar
• Foley RN, Herzog CA, Collins AJ. Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 study. Kidney Int 2003;63:462-7
   Google Scholar
• Sarnak MJ, Levey AS. Epidemiology of cardiac disease in dialysis patients. Semin Nephrol 1999;12:69-76
   Google Scholar
• Schffrin EL, Lipman ML, Mann JEF. Chronic kidney disease. Effects on the cardiovascular system. Circulation 2007;116:85-97
   PubMedGoogle Scholar
• Go AS, Chertow GM, Fan D, Chronic renal disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305
   PubMed Web of Science ®Google Scholar
• Jungers P, Massy ZA, Khoa TN, Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant 1997;12:2597-602
   PubMed Web of Science ®Google Scholar
• Manjunath G, Tighiouart H, Ibrahim H, Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003;41:47-55
   PubMed Web of Science ®Google Scholar
• Levin A, Djurdjev G, Barrett B, Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis 2001;38:1398-407
   PubMed Web of Science ®Google Scholar
• Iguchi Y, Kimura K, Kobayashi K, Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol 2008;102:1056-9
   PubMed Web of Science ®Google Scholar
• Auer J, Lamm G, Weber T, Renal function is associated with risk of atrial fibrillation after cardiac surgery. Can J Cardiol 2007;23:859-63
   PubMedGoogle Scholar
• Böhm M, Thoenes M, Neuberger HR, Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients. Eur Heart J 2009;30:1364-71
   PubMedGoogle Scholar
• Go AS, Fang MC, Udaltsova N, Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009;119:1363-9
   PubMed Web of Science ®Google Scholar
• Herzog CA, Mangrum JM, Passman R. Sudden cardiac death and dialysis patients. Semin Dial 2008;21:300-7
   PubMed Web of Science ®Google Scholar
• Turner S, Onalan O, Bickle B. Prevention of death in chronic kidney disease: the role of implantable cardioverter defibrillators. CANNT J 2009;19:29-36
   PubMedGoogle Scholar
• Cuculich PS, Sánchez JM, Kerzner R, Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death. Pacing Clin Electrophysiol 2007;30:207-13
   PubMedGoogle Scholar
• Korantzopoulos P, Liu T, Li L, Implantable cardioverter defibrillator therapy in chronic kidney disease: a meta-analysis. Europace 2009;11:1469-75
   PubMedGoogle Scholar
• Sakhuja R, Keebler M, Lai TS, Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillator. Am J Cardiol 2009;103:735-41. [Epub ahead of print]
   PubMedGoogle Scholar
• Baigent C, Landray M. Which cardiovascular risk factors matter in chronic kidney disease? Nephrol Dial Transplant 2007;22:9-11
   PubMedGoogle Scholar
• Shlipack MG, Fried LF, Cushman M, Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005;293:1737-45
   PubMedGoogle Scholar
• Rysz J, Aronow WS, Stolarek RS, Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets 2009;13:541-50
   PubMed Web of Science ®Google Scholar
• Weiner DE, Tighiouart H, Elsayed EF, The relationship between non-traditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am J Kidney Dis 2008;51:212-23
   PubMedGoogle Scholar
• Kazmi WH, Kausz AT, Khan S, Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 2001;38:803-12
   PubMed Web of Science ®Google Scholar
• Weiner DE, Tighouart H, Vlagopoulos PT, Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic renal disease. J Am Soc Nephrol 2005;16:1803-10
   PubMed Web of Science ®Google Scholar
• Ofsthun N, Labrecque J, Lacson E, The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003;63:1908-14
   PubMed Web of Science ®Google Scholar
• Portoles J, Lopez-Gomez JM, Aljama P, MAR Study Group. A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients. Nephrol Dial Transplant 2007;22:500-7
   PubMedGoogle Scholar
• Regidor DL, Kopple JD, Kovesky CP, Associations between changes in hemoglobin and administered erythropoioiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:181-91
   Google Scholar
• Besarab A, Bolton WK, Browne JK, The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoietin. N Engl J Med 1998;339:584-90
   PubMed Web of Science ®Google Scholar
• Drueke TB, Locatelli F, Clyne N, Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, Correction of anemia with Epoetin alpha in chronic renal disease. N Engl J Med 2006;355:2085-98
   PubMed Web of Science ®Google Scholar
• Locatelli F, Covic A, Eckardt KU, ERA-EDTA ERBP Advisory Board: Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009;24:348-54
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Burdmann EA, Chen CY, Trial of darbepoietin alfa in Type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32
   PubMed Web of Science ®Google Scholar
• Martin de Francisco AL, Aljama P, Arias M, Corrección de la anemia en pacientes diabéticos com enfermedad renal crónica sin tratamiento sustitutivo: enseñanzas del estudiom TREAT. Nefrologia 2010;30:15-20
   PubMedGoogle Scholar
• KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease. 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530
   PubMed Web of Science ®Google Scholar
• Deved V, Poyah P, James MT, Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. Am J Kidney Dis 2009;54:1089-97
   PubMed Web of Science ®Google Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, Association of serum phosphorus and calciumxphosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17
   PubMed Web of Science ®Google Scholar
• Ganesh SK, Stack AG, Levin NW, Association of elevated serum PO(4), Ca x PO(4) product and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8
   PubMed Web of Science ®Google Scholar
• Kestenbaum B, Sampson JN, Rudser KD, Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-8
   PubMed Web of Science ®Google Scholar
• Kidney Disease. Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;13(Suppl 1):1-130
   Google Scholar
• Dhingra R, Sullivan LM, Fox CS, Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007;167:879-85
   PubMed Web of Science ®Google Scholar
• Raggi P, Boulay A, Chasan-Taber S, a link between end-stage renal disease and cardiovascular disease. J Am Coll Cardiol 2002;39:695-701
   PubMed Web of Science ®Google Scholar
• Suki W, Zabaneh R, Cangiano JL, Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7
   PubMed Web of Science ®Google Scholar
• Qunibi W, Moustafa M, Muenz LR, A 1-year randomized trial of calcium acetate vs. sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2). Am J Kidney Dis 2008;51:952-65
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Palmer SC, Craig JC, Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;54:619-37
   PubMed Web of Science ®Google Scholar
• Chertow G, Pupim L, Block G, Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007;2:898-905
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2006;2:582-93
   PubMedGoogle Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115-26
   PubMed Web of Science ®Google Scholar
• Goldstein SL, Leung JC, Silverstein DM. Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of aspirin. Clin J Am Soc Nephrol 2006;1:979-86
   PubMedGoogle Scholar
• Valkonen VP, Päivä H, Salonen JT, Risk of acute coronary events and concentration of asymmetrical methylarginine. Lancet 2001;358:2127-8
   PubMed Web of Science ®Google Scholar
• Fliser D, Kronenberg F, Kielstein JT, Asymmetrical dimethylarginine and the progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005;16:2456-61
   PubMed Web of Science ®Google Scholar
• Zoccali C, Bode-Böger S, Mallamaci F, Plasma concentrations of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-17
   PubMed Web of Science ®Google Scholar
• Drexler H, Zeiher AM, Meinzer K, Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991;338:1546-50
   PubMed Web of Science ®Google Scholar
• Lerman A, Burnett JC Jr, Higano ST, Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 1998;97:2123-8
   PubMed Web of Science ®Google Scholar
• Boaz M, Smetana S, Weinstein T, Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomized placebo-controlled trial. Lancet 2000;356:1213-18
   PubMed Web of Science ®Google Scholar
• Tepel M, van der Giet M, Statz M, The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003;107:992-5
   PubMed Web of Science ®Google Scholar
• Homocysteine studies collaboration study. Homocysteine and risk of ischemic heart disease and stroke. JAMA 2002;288:2015-22
   PubMedGoogle Scholar
• Mallamaci F, Zoccali C, Tripepi G, ; on behalf of the CREED Investigators. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002;61:609-14
   PubMed Web of Science ®Google Scholar
• Menon V, Sarnak MJ, Greene T, Relationship between homocysteine and mortality in chronic kidney disease. Circulation 2006;113:1572-7
   PubMedGoogle Scholar
• Suliman ME, Stenvinkel P, Bárány P, Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus. Am J Kidney Dis 2003;41(3 Suppl 1):89-95
   Google Scholar
• Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 2005;68:1973-81
   PubMed Web of Science ®Google Scholar
• Zittermann A, Schleithoff SS, Tenderich G, Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003;41:105-12
   PubMed Web of Science ®Google Scholar
• Freundlich M, Quiroz Y, Zhang Z, Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008;74:1394-2
   PubMed Web of Science ®Google Scholar
• Stubbs JR, Idiculla A, Slusser J, Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 2010;21:353-61
   PubMed Web of Science ®Google Scholar
• Levin A. The need for optimal and coordinated management of CKD. Kidney Int 2005;68(Suppl 99):7-10
   Google Scholar
• Valderrabano F, Golper T, Muirhead N, Chronic kidney disease: why is current management uncoordinated and suboptimal. Nephrol Dial Transplant 2001;16(Suppl 7):61-4
   PubMedGoogle Scholar
• Abboud H, Henrich WL. Clinical practice. Stage IV chronic kidney disease. N Engl J Med 2010;362:56-65
   PubMedGoogle Scholar
• Rodriguez-Iturbe B, García-García G. Pathophysiology and treatment of CKD. Hypertension and dyslipidemia in the pathophysiology of chronic kidney disease. Arch Med Sci 2009;5(Suppl 3A):395-414
   Google Scholar
• Riegersperger M, Sunder-Plassmann G. How to prevent progression to end stage renal disease. Ren Care 2007;33:105-7
   PubMedGoogle Scholar
• Walker DB, Walker TJ, Jacobson TA. Chronic kidney disease and statins: improving cardiovascular outcomes. Curr Atheroscler Rep 2009;11:301-8
   PubMed Web of Science ®Google Scholar
• Palmer SC, McGregor DO, Craig JC, Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev 2009;4:CD005633
   PubMed Web of Science ®Google Scholar
• Chauhan V, Vaid M. Dyslipidemia in chronic kidney disease: managing a high-risk combination. Postgrad Med 2009;121:54-61
   PubMed Web of Science ®Google Scholar
• Williamson DF, Vinicor F, Bowman BA, Centers for Disease Control And Prevention Primary Prevention Working Group. Primary prevention of type 2 diabetes mellitus by lifestyle intervention: implications for health policy. Ann Intern Med 2004;140:951-7
   PubMedGoogle Scholar
• World Health Organization. Obesity and Overweight. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html [Last accessed 7 April 2010]
   Google Scholar
• Whitlock G, Lewington S, Sherliker P, Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373:1083-96
   PubMed Web of Science ®Google Scholar
• Morales E, Valero MA, Leon M, Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003;41:319-27
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Yehnert H, Moustarah F, Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009;4:1565-74
   PubMed Web of Science ®Google Scholar
• Leavy SD, Strawderman RL, Jones CA, Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis 1998;31:997-1006
   PubMedGoogle Scholar
• Kopple JD, Zhu X, Lew NL, Body weight-for-height relationships predict mortality in hemodialysis patients. Kidney Int 1999;56:1136-48
   PubMed Web of Science ®Google Scholar
• Abbott KC, Glanton CW, Trespalacios FC, Body mass index, dialysis modality and survival: analysis of the United States Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int 2004;65:597-605
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh, Block G, Humphreys MH, Reverse epidemiology of cardiovascular disease risk factors in maintenance dialysis. Kidney Int 2003;63:793-808
   PubMed Web of Science ®Google Scholar
• Knight EL, Stampfer MJ, Rimm EB, Moderate alcohol intake and renal function decline in women: a prospective study. Nephrol Dial Transplant 2003;18:1549-54
   PubMedGoogle Scholar
• Van Thiel DH, Williams WD Jr, Gavaler JS, Ethanol – its nephrotoxic effect in the rat. Am J Pathol 1977;89:67-83
   PubMed Web of Science ®Google Scholar
• Perneger TV, Whelton PK, Puddey IB, Risk of endstage renal disease associated with alcohol consumption. Am J Epidemiol 1999;150:1275-81
   PubMed Web of Science ®Google Scholar
• Ritz E, Schwenger V. Lifestyle modification and progressive renal failure. Nephrology 2005;10:387-92
   PubMedGoogle Scholar
• Pinto-Sietsma SJ, Mulder J, Janssen WM. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000;133:585-91
   PubMed Web of Science ®Google Scholar
• Mimran A, Ribstein J, Ducailar G, Albuminuria in normal and essential hypertension. J Diabetes Complications 1994;8:150-6
   PubMedGoogle Scholar
• Kasiske BL, Linger D. Cigarette smoking in renal transplant recipients. J Am Soc Nephrol 2000;11:753-9
   PubMedGoogle Scholar
• Bleyer AJ, Shemanski LR, Burke GL, Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney Int 2000;57:2072-9
   PubMed Web of Science ®Google Scholar
• Goetz FC, Jacobs DR Jr, Chavers B, Risk factors for kidney damage in the adult population of Wadena, Minnesota. A prospective study. Am J Epidemiol 1997;145:91-102
   PubMedGoogle Scholar
• He FJ, Macgregor GA. A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. J Hum Hypertens 2008;23:363-84
   PubMed Web of Science ®Google Scholar
• World Health Organization. The World Health Report 2002. Reducing risks, promoting healthy life. 2002. Available from: www.who.int/whr/2002/en/ [Last accessed 7 April 2010]
   Google Scholar
• Palar K, Sturm R. Potential societal savings from reduced sodium consumption in the US adult population. Am J Health Promot 2009;24:49-57
   PubMed Web of Science ®Google Scholar
• Bibbins-Domingo K, Chertow GM, Coxson PG, Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med 2010;362:590-9
   PubMed Web of Science ®Google Scholar
• Rodriguez-Iturbe B, Romero F, Johnson RJ. Pathophysiologic mechanisms of salt-dependent hypertension. Am J Kidney Dis 2007;50:655-72
   PubMed Web of Science ®Google Scholar
• Strazzullo P, D'Elia L, Kandala N-B, Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. Br Med J 2009;339:b4567
   PubMed Web of Science ®Google Scholar
• Krikken JA, Laverman GD, Navis G, Benefits of dietary sodium restriction in the management of chronic kidney disease. Curr Opin Nephrol Hypertens 2009;18:531-8
   PubMed Web of Science ®Google Scholar
• Segura J, Ruilope LM. Should diuretics always be included as initial antihypertensive management in early-stage CKD? Curr Opin Nephrol Hypertens 2009;18:392-6
   PubMedGoogle Scholar
• Physical activity trends – United States, 1990 – 1998. MMWR MorbMortal Wkly Rep 2001;50:166-9
   PubMedGoogle Scholar
• Lamonte MJ, Yanowitz FG. Aerobic exercise for lowering blood pressure: a metaanalysis. Clin J Sport Med 2002;12:407
   PubMedGoogle Scholar
• Cukor D, Cohen SD, Peterson RA, Psychosocial aspects of chronic disease: ESRD as a paradigmatic illness. J Am Soc Nephrol 2007;18:3042-55
   PubMed Web of Science ®Google Scholar
• Cohen SD, Sharma T, Acquaviva K, Social support and chronic kidney disease: an update. Adv Chronic Kidney Dis 2007;14:335-44
   PubMedGoogle Scholar
• Lii YC, Tsay SL, Wang TJ. Group intervention to improve quality of life in haemodialysis patients. J Clin Nurs 2007;16:268-75
   PubMed Web of Science ®Google Scholar
• Levin A. Predicting outcomes in CKD: the importance of perspectives, populations and practices. Nephrol Dial Transplant 2009;24:1724-6
   PubMedGoogle Scholar
• Ruilope LM, Segura J. The importance of integrated risk management when treating patients with hypertension: benefits of angiotensin II receptor antagonist therapy. Clin Exp Hypertens 2008;30:397-414
   PubMed Web of Science ®Google Scholar
• Schwedt E, Solá L, Ríos PG, Improving the management of chronic kidney disease in uruguay: a national renal healthcare program. Nephron Clin Pract 2009;114:c47-59
   PubMedGoogle Scholar
• Beaulieu M, Levin A. Analysis of multidisciplinary care models and interface with primary care in management of chronic kidney disease. Semin Nephrol 2009;29:467-74
   PubMedGoogle Scholar
• Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications. Am J Kidney Dis 2009;53(Suppl 3):S4-16
   Google Scholar
• Stevens PE, O'Donoghue DJ. The UK model for system redesign and chronic kidney disease services. Semin Nephrol 2009;29:475-82
   PubMedGoogle Scholar
• World Health Organization. 2008-2013 Action Plan for Global Strategy for the Prevention and Control of Non-communicable Diseases. 2008, p1-p42. Accessed April 7, 2010 from http://www.who.int/nmh/publications/2009/9789241597418-eng.pdf
   Google Scholar